About one in 10 prescription drugs—mainly brand-name and expensive drugs and those for rare diseases—has a manufacturer-sponsored patient support program, which usually includes financial, nursing and educational supports.
Nov 27, 2023
0
0
A new drug to treat postpartum depression will cost nearly $16,000 for a 14-day course of treatment, a price tag that has doctors worried that some patients won't be able to afford the medication.
Nov 8, 2023
0
11
The U.S. government could save taxpayers between $228 million and $2.15 billion a year if insurers who operate its Medicare Part D plans purchased seven generic oncology drugs at the same prices obtained by the Mark Cuban ...
Jun 8, 2023
0
16
Merck filed a lawsuit Tuesday challenging a new White House-backed program to limit drug prices, calling the initiative an unconstitutional "extortion" that will harm pharmaceutical innovation.
Jun 6, 2023
0
1
The U.S. biosimilar drug market emerged in 2015 to provide safe, effective, and more affordable alternatives to existing biologic drugs, but it has been slow to develop compared with Europe.
Jun 6, 2023
0
1
Catherine Reitzel's multiple sclerosis medication costs nearly $100,000 a year. Kris Garcia relies on a drug for a blood-clotting disorder that runs $10,000 for a three-day supply. And Mariana Marquez-Farmer would likely ...
May 31, 2023
0
19
Although the Inflation Reduction Act of 2022 (IRA) aimed to increase patient access to prescription drugs and decrease spending, researchers warn that it may have unintended negative impacts on patients in the long run.
Apr 13, 2023
0
10
The U.S. government could save billions every year once Medicare begins negotiating drug prices in 2026, new research suggests.
Jan 30, 2023
0
0
Canada's drug prices are the fourth highest in the developed world. Despite this, Innovative Medicines Canada (IMC), the lobby group for Big Pharma, put out a call in November 2022 for the Canadian government to suspend consultations ...
Jan 10, 2023
0
9
A cost-effectiveness analysis comparing direct oral anticoagulants (DOACs) to low-molecular-weight heparin (LMWH) found that DOACs are both more medically effective and cost-effective than LMWH when treating cancer-associated ...
Dec 26, 2022
0
18
